Milestone begins Canadian enrolment in Phase III AFib-RVR trial
Milestone Pharmaceuticals has enrolled the first Canadian participant in its ongoing multinational Phase III clinical trial, ReVeRA-301.
The post Milestone begins Canadian enrolment in Phase III AFib-RVR trial appeared first on Clinical Trials Arena .